Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 29, 1999
Grant Date -
N/A
app pub date -
Feb 11, 1998
filing date -
Jun 7, 1995
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A method for increasing bioavailabilty of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration 0.01 wt. % or less in an assay that measures reduced conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 .mu.M reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1 M sodium phosphate buffer, pH 7.4.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully